FDA panel backs Bluebird gene therapy despite safety risks
June 9, 2022Forbion raises $500M to back growing biotechs amid industry slump
June 10, 2022Following a marathon session of the FDA’s Cell, Tissue and Gene Therapies Advisory Committee, bluebird bio passed its first critical hurdle in approval for the lentiviral vector gene therapy, eli-cel.
